Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006146 | 0.95 | ARG1 (0.66) | ARG1ARG2 | |
| SCHEMBL25865758 | 0.90 | ARG1 (0.54) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL2563248 | 0.89 | ARG1 (0.76) | ARG1ARG2 | |
| SCHEMBL894921 | 0.89 | ARG1 (0.79) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895047 | 0.88 | ARG1 (0.77) | ARG1ARG2 | |
| SCHEMBL1740434 | 0.87 | ARG1 (0.76) | ARG1ARG2 | |
| SCHEMBL27921023 | 0.87 | ARG1 (0.76) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895023 | 0.86 | ARG1 (0.76) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL28034065 | 0.85 | ARG1 (0.74) | ARG1ARG2 | |
| SCHEMBL894958 | 0.80 | ARG1 (1.00) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | ARG1 25/4885ARG2 29/4885 |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | FUT6, FUT5, OGT | ARG1 846/4885ARG2 349/4885 |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | ARG1 25/4885ARG2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.